DYN

← Markets

DYNDyne Therapeutics, Inc.

Discussion

Nothing said here yet.

to join the conversation.


Rhodes Jason PDirector	Sell	1,359,674	$34.0M	Fri, Aug 14
Rhodes Jason PDirector	Sell	478,377	$12.0M	Fri, Aug 14
Rhodes Jason PDirector	Sell	322,465	$8.1M	Fri, Aug 14
Rhodes Jason PDirector	Sell	268,354	$7.0M	Thu, Aug 13
Rhodes Jason PDirector	Sell	94,415	$2.5M	Thu, Aug 13
Rhodes Jason PDirector	Sell	63,643	$1.7M	Thu, Aug 13
Cox JohnCEO & President	Sell	4,986	$131.0K	Thu, Aug 13
Lucera ErickChief Financial Officer	Sell	1,797	$47.2K	Thu, Aug 13
Kerr DouglasChief Medical Officer	Sell	1,556	$40.9K	Thu, Aug 13
Friedl-Naderer JohannaChief Commercial Officer	Sell	226	$5.9K	Thu, Aug 13

Rhodes Jason PDirector

Sell

1,359,674

$34.0M

Fri, Aug 14

Rhodes Jason PDirector

Sell

478,377

$12.0M

Fri, Aug 14

Rhodes Jason PDirector

Sell

322,465

$8.1M

Fri, Aug 14

Rhodes Jason PDirector

Sell

268,354

$7.0M

Thu, Aug 13

Rhodes Jason PDirector

Sell

94,415

$2.5M

Thu, Aug 13

Rhodes Jason PDirector

Sell

63,643

$1.7M

Thu, Aug 13

Cox JohnCEO & President

Sell

4,986

$131.0K

Thu, Aug 13

Lucera ErickChief Financial Officer

Sell

1,797

$47.2K

Thu, Aug 13

Kerr DouglasChief Medical Officer

Sell

1,556

$40.9K

Thu, Aug 13

Friedl-Naderer JohannaChief Commercial Officer

Sell

226

$5.9K

Thu, Aug 13

Thu, Aug 20
3:05 PMglobenewswire.comDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wed, Jul 29
3:30 PMYahooDyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Tue, Jul 28
6:30 AMYahooDyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Thu, Jul 23
3:05 PMYahooDyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
6:08 AMYahooDyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling?
Wed, Jul 22
8:25 AMYahooSRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?
7:29 AMinvestorshub.advfn.comDyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN)
Tue, Jul 21
9:46 PMYahooDyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
7:06 PMstocktwits.comWhy DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock
3:46 PMYahooDyne Therapeutics Announces Proposed Public Offering of Common Stock
9:20 AMYahooDYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
Mon, Jul 20
6:30 AMYahooDyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)